These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28861320)

  • 21. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes.
    Lee JK; Mathew SO; Vaidya SV; Kumaresan PR; Mathew PA
    J Immunol; 2007 Oct; 179(7):4672-8. PubMed ID: 17878365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes.
    Wang YH; Hagiwara S; Kazama H; Iizuka Y; Tanaka N; Tanaka J
    J Immunol Res; 2024; 2024():1429879. PubMed ID: 38444839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.
    Taniwaki M; Yoshida M; Matsumoto Y; Shimura K; Kuroda J; Kaneko H
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018014. PubMed ID: 29531651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. YY1 and a unique DNA repeat element regulates the transcription of mouse CS1 (CD319, SLAMF7) gene.
    Dongre P; Mathew S; Akopova I; Gryczynski I; Mathew P
    Mol Immunol; 2013 Jul; 54(3-4):254-63. PubMed ID: 23318224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CS1 Expression Pattern in NK Cells and Correlated Factors in Plasma Cell dyscrasias: Implications for Elotuzumab Therapy and CAR-T Efficacy.
    Li C; Wang D; Xu Y; Mao X; Que Y; Li Z; Yu Q; Xu M; An N; Long X; Li C
    J Cancer; 2024; 15(10):3065-3075. PubMed ID: 38706917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes.
    Kim JR; Horton NC; Mathew SO; Mathew PA
    Inflamm Res; 2013 Aug; 62(8):765-72. PubMed ID: 23695528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
    Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
    J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1
    Lum LG; Thakur A; Elhakiem A; Alameer L; Dinning E; Huang M
    Front Oncol; 2020; 10():544. PubMed ID: 32432032
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
    Friend R; Bhutani M; Voorhees PM; Usmani SZ
    Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.
    Chen WC; Kanate AS; Craig M; Petros WP; Hazlehurst LA
    Cancer Manag Res; 2017; 9():307-314. PubMed ID: 28744161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.
    Golubovskaya V; Zhou H; Li F; Berahovich R; Sun J; Valentine M; Xu S; Harto H; Sienkiewicz J; Huang Y; Wu L
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
    Chu E; Wu J; Kang SS; Kang Y
    Curr Oncol; 2023 Aug; 30(9):7891-7903. PubMed ID: 37754488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE.
    Humbel M; Bellanger F; Fluder N; Horisberger A; Suffiotti M; Fenwick C; Ribi C; Comte D
    Front Immunol; 2021; 12():645478. PubMed ID: 33828555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of SLAMF7 in multiple myeloma: impact on therapy.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma.
    Ishibashi M; Morita R; Tamura H
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33451089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs.
    Lee JK; Boles KS; Mathew PA
    Eur J Immunol; 2004 Oct; 34(10):2791-9. PubMed ID: 15368295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.